Atrial natriuretic hormone, vessel dilator, long acting natriuretic hormone, and kaliuretic hormone decrease circulating prolactin concentrations

Hormone and Metabolic Research

Volumn 34, Issue 5, 2002, Pages 245-249

  Vesely, David L ^a,b,c   San Miguel, G I ^a,b,c   Hassan, I ^a,b,c   Schocken, D D ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Corticotropin Releasing Hormone; Hypothalamus; Natriuretic Hormones; Prolactin Inhibitory Hormones

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CORTICOTROPIN RELEASING FACTOR; DOPAMINE; KALIURETIC HORMONE; NATRIURETIC FACTOR; PROLACTIN; PROLACTOSTATIN; UNCLASSIFIED DRUG; VESSEL DILATOR HORMONE; ATRIAL NATRIURETIC FACTOR PRECURSOR (79 98); ATRIAL NATRIURETIC FACTOR PRECURSOR (79-98); ATRIAL NATRIURETIC FACTOR PROHORMONE (31 67); ATRIAL NATRIURETIC FACTOR PROHORMONE (31-67); PEPTIDE FRAGMENT; PROTEIN PRECURSOR;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPOTHALAMUS; INFUSION; MALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; REGULATORY MECHANISM; BLOOD; CHEMICAL PHENOMENA; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED;

ADULT; ATRIAL NATRIURETIC FACTOR; DEPRESSION, CHEMICAL; FEMALE; HUMAN; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGE; PEPTIDE FRAGMENTS; PROLACTIN; PROTEIN PRECURSORS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; HUMANS; MIDDLE AGED;

EID: 0035989067     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-32137     Document Type: Article

References (36)

1. Effect of α-human atrial natriuretic polypeptide on anterior pituitary function in men
2. Evidence of immunoreactive human atrial peptides in human anterior pituitary cells
3. Evidence for a dopaminergic involvement in the inhibitory effect of alpha human natriuretic peptide on prolactin in man
4. Atrial natriuretic hormone inhibits corticotropin-releasing hormone-induced prolactin release in man
5. Expression of the gene for preproatriopeptin in the central nervous system of the rat
6. 2-terminuteus are natriuretic and/or kaliuretic
7. Atrial natriuretic prohormone peptides 1-30, 31-67 and 79-98 vasodilate the aorta
8. Negative feedback of atrial natriuretic peptides
9. Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce a diuresis, natriuresis, and/or kaliuresis in humans
10. Vessel dilator enhances sodium and water excretion and has beneficial hemodynamic effects in persons with congestive heart failure
11. Increased release of the N-terminal and C-terminal portions of the prohormone of atrial natriuretic factor during immersion-induced central hypervolemia in normal humans
12. The N-terminus and a 4000 molecular weight peptide from the mid portion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure
13. Analysis of peptides derived from pro atrial natriuretic peptide that circulate in man and increase in heart disease
14. Pharmacokinetic characterization of the post-distribution phase of prohormone atrial natriuretic peptides amino acids 1-98, 31-67, and atrial natriuretic factor during and following rapid right ventricular pacing in dogs
15. Congestive heart failure: Increased cardiac and extracardiac atrial natriuretic peptide gene expression
16. Release of ANF, proANF 1-98, and proANF 31-67 from isolated rat atria by atrial distention
17. Disposition of vessel dilator and long-acting natriuretic peptide in healthy humans following a one-hour infusion
18. Corticotropin-releasing factor (CRF): A common link between anterior pituitary and sympathetic responses to stress
19. Atrial natriuretic hormone, vessel dilator, long-acting natriuretic hormone, and kaliuretic hormone decrease the circulating concentrations of corticotropin-releasing hormone, corticotropin and cortisol
20. Partial characterization of the neurotransmitter pathway regulating the in vitro release of prolactin
21. Further evidence for a hypothalamic site of action of atrial natriuretic factor: Inhibition of prolactin secretion in the conscious rat
22. Evidence for a dopaminergic mechanism for the prolactin inhibitory effect of atrial natriuretic factor
23. Atrial and brain natriuretic peptides enhance dopamine accumulation in cultured hypothalamic cells including dopaminergic neurons
24. Inhibitory effect of centrally administered atrial natriuretic polypeptide on brain dopaminergic system in rats
25. Atrial natriuretic polypeptide: Topographical distribution in the rat brain by radioimmunoassay and immunochemistry
26. Localization and characterization of atrial natriuretic peptide binding sites in discrete areas of rat brain and pituitary gland by quantitative autoradiography
27. Characterization of high affinity receptor sites for atrial natriuretic factor in anterior pituitary gland: Evidence for the existence of two receptor forms
28. Differential regional expression of three natriuretic peptide receptor genes within primate tissues
29. Localization of mRNA coding for three subtypes of atrial natriuretic factor (ANF) receptors in rat anterior pituitary gland cells
30. Atrial natriuretic peptide in brain and pituitary gland
31. The effect of splanchnic nerve stimulation on the uptake of atrial natriuretic peptide by the adrenal gland of conscious calves
32. Atrial natriuretic peptide-like immunoreactive material (ANP-LI) is released from the adrenal gland by splanchnic stimulation
33. Prolactin and its disorders
34. Prohormone atrial natriuretic peptides 1-30 and 31-67 increase in hyperthyroidism and decrease in hypothyroidism
35. Serum prolactin levels in untreated primary hypothyroidism